Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.35 |
| ▸ | IL6ST | P40189 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 3/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21075769 | 1.00 | MAPK1 (0.36) | MAPK1ATMNAAAIL6STPOLB | |
| SCHEMBL6806230 | 0.84 | NAAA (0.33) | NAAAIL6STACE | |
| SCHEMBL19084016 | 0.80 | IL6ST (0.43) | NAAAIL6STACE | |
| SCHEMBL19083745 | 0.80 | NAAA (0.33) | NAAAIL6STPOLBACE | |
| SCHEMBL9973253 | 0.76 | NAAA (0.46) | MAPK1NAAAIL6STPOLBELANE | |
| SCHEMBL3333540 | 0.76 | P2RX7 (0.39) | MAPK1NAAAACE | |
| SCHEMBL22708254 | 0.76 | P2RX7 (0.39) | MAPK1NAAAACE | |
| SCHEMBL7484640 | 0.76 | P2RX7 (0.39) | MAPK1NAAAACE | |
| SCHEMBL11305102 | 0.73 | ACE (0.48) | ACE | |
| SCHEMBL3336304 | 0.72 | P2RX7 (0.45) | NAAAACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | MAPK1 4290/4885ATM 4395/4885NAAA 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.